These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 6399040)

  • 1. [Clinical experience with cefonicid in infectious pneumopathies].
    Guarino C; Cautiero V; Paone G; Presutto A; Santoro E
    G Ital Chemioter; 1984; 31(3):259-65. PubMed ID: 6399040
    [No Abstract]   [Full Text] [Related]  

  • 2. A randomized clinical trial comparing the safety and efficacy of cefonicid and cefamandole in the treatment of patients with respiratory tract infections caused by susceptible pathogens.
    Azanza JR; Honorato J; Rubio A; Cuena R
    Chemioterapia; 1987 Jun; 6(2 Suppl):449-51. PubMed ID: 3334597
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of cefonicid and cefamandole for the treatment of community-acquired infections of the lower respiratory tract.
    Geckler RW; McCormack GD; Goodman JS
    Rev Infect Dis; 1984; 6 Suppl 4():S847-52. PubMed ID: 6395275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy and tolerance of cefonicid in the treatment of respiratory infections].
    Bolognini G; Biage GI
    Recenti Prog Med; 1987 Jun; 78(6):311-2. PubMed ID: 3659557
    [No Abstract]   [Full Text] [Related]  

  • 5. [Update on antibiotic therapy. 30) Cefonicid].
    di Nola F
    Minerva Med; 1985 Apr; 76(16):819-25. PubMed ID: 4000526
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of once-daily cephalosporin regimens for community-acquired lower respiratory tract infections in patients with chronic lung disease.
    McCabe RE; Schlossberg D; Donowitz GR; Scheld WM; Zellner SR; Lindenberg LB; Armstrong JH; Ein ME
    Clin Ther; 1989; 11(3):304-14. PubMed ID: 2663160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview: evaluation of cefonicid in infections of the urinary tract, lower respiratory tract, and skin and soft tissue.
    Kaye D
    Rev Infect Dis; 1984; 6 Suppl 4():S835-8. PubMed ID: 6522926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefonicid: an overview of clinical studies in the United States.
    Jacob LS; Layne P
    Rev Infect Dis; 1984; 6 Suppl 4():S791-802. PubMed ID: 6395272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy of cefonicid in the treatment of staphylococcal infections.
    Lentnek AL; Evrard HM; Wikler MA; Sohn CA; Phillips SW
    Clin Ther; 1985; 7(6):725-32. PubMed ID: 4075363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of urinary tract infections in hospitalized patients: a double-blind comparison of cefonicid and cefamandole.
    Cox CE; Jacob LS
    Rev Infect Dis; 1984; 6 Suppl 4():S839-43. PubMed ID: 6395273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of cefonicid in children.
    Furlanut M; D'Elia R; Riva E; Pasinelli F
    Eur J Clin Pharmacol; 1989; 36(1):79-82. PubMed ID: 2917594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cefonicid (SK&F D-75073-Z2) in a single low dose in the treatment of complicated infections of the urinary tract].
    Salvadeo A; Hartwig J; Perduca M; Villa G
    G Ital Chemioter; 1984; 31(1-2):127-32. PubMed ID: 6468823
    [No Abstract]   [Full Text] [Related]  

  • 13. Cefonicid sodium (Monocid).
    Med Lett Drugs Ther; 1984 Aug; 26(667):71-2. PubMed ID: 6379400
    [No Abstract]   [Full Text] [Related]  

  • 14. [Double-blind comparison of cefamandole and cefazolin in the therapy of respiratory tract infections (author's transl)].
    Jpn J Antibiot; 1980 Mar; 33(3):375-409. PubMed ID: 6995640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-generation cephalosporins.
    Glatt AE
    Hosp Pract (Off Ed); 1986 Mar; 21(3):158A-158B, 158E, 158H-158L. PubMed ID: 3081544
    [No Abstract]   [Full Text] [Related]  

  • 16. Cefonicid: a long-acting, second-generation cephalosporin. Antimicrobial activity, pharmacokinetics, clinical efficacy and adverse effects.
    Pontzer RE; Kaye D
    Pharmacotherapy; 1984; 4(6):325-33. PubMed ID: 6393074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trial of cefonicid for treatment of skin infections.
    Gremillion DH; Winn RE; Vandenbout E
    Antimicrob Agents Chemother; 1983 Jun; 23(6):944-6. PubMed ID: 6351735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of cefonicid use in a general hospital.
    Rodríguez C; Colomé E; Arnau JM; Jodar R; Montoro B; Cano M; Laporte JR
    DICP; 1989 Feb; 23(2):154-6. PubMed ID: 2728506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of long half-life parenteral cephalosporins in ambulatory practice.
    Sauerwein M; Deamer RL; Prichard JG
    J Fam Pract; 1987 Jan; 24(1):47-51. PubMed ID: 3794613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of cefonicid and cefazolin for treatment of soft-tissue infections.
    Slutkin G; Marzouk J; Dall L; Mills J
    Rev Infect Dis; 1984; 6 Suppl 4():S853-6. PubMed ID: 6395276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.